Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00061178
Status:
WITHDRAWN
Last Update Posted:
2016-10-19
First Post:
2003-05-21
Brief Title:
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
Phase III Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Efficacy Safety of rhuMAb VEGF in Previously Treated Metastatic Renal Cell Carcinoma
Status:
WITHDRAWN
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No patients were enrolled study cancelled before start
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether rhuMAb VEGF Bevacizumab is safe and effective for the treatment of renal cell cancer when other treatments have failed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None